WallStreetZenWallStreetZen

NASDAQ: AKYA
Akoya Biosciences Inc Stock Forecast, Predictions & Price Target

OverviewForecast
EarningsRevenueDividendOwnership

Analyst price target for AKYA

Based on 3 analysts offering 12 month price targets for Akoya Biosciences Inc

Min Forecast
$1.08-14.29%
Avg Forecast
$1.51+19.84%
Max Forecast
$1.80+42.86%

Should I buy or sell AKYA stock?

Based on 3 analysts offering ratings for Akoya Biosciences Inc.

Hold
Strong Buy
0 analysts 0%
Buy
0 analysts 0%
Hold
3 analysts 100%
Sell
0 analysts 0%
Strong Sell
0 analysts 0%

Be the first to know when Wall Street analysts revise their AKYA stock forecasts and price targets.

AKYA stock forecasts by analyst

Analyst / FirmRatingActionPrice TargetUpside/DownsideDateAnalyst Color
lockedlocked$00.00+00.00%2025-05-19
lockedlocked$00.00+00.00%2025-04-14
lockedlocked$00.00+00.00%2025-03-25

1 of 1

Forecast return on equity

Is AKYA forecast to generate an efficient return?

Forecast return on assets

Is AKYA forecast to generate an efficient return on assets?

Company
-20.07%
Industry
12.62%
AKYA is forecast to generate... subscribe to Premium to read more.
Forecast Return on Assets vs Industry Forecast

AKYA earnings per share forecast

What is AKYA's earnings per share in the next 3 years based on estimates from 4 analysts?

Avg 1 year Forecast
-$0.83
Avg 2 year Forecast
-$0.65
Avg 3 year Forecast
-$0.45

AKYA revenue forecast

What is AKYA's revenue in the next 3 years based on estimates from 2 analysts?

Avg 1 year Forecast
$85.0M+6.25%
Avg 2 year Forecast
$95.9M+19.95%
Avg 3 year Forecast
$105.1M+31.41%
AKYA's revenue is forecast to... subscribe to Premium to read more.
Forecast High Revenue Growth Forecast

AKYA revenue growth forecast

How is AKYA forecast to perform vs Medical Instruments & Supplies companies and vs the US market?

Company
9.18%
Industry
8.53%
Market
9.8%
AKYA's revenues are forecast to... subscribe to Premium to read more.
Forecast Revenue Growth vs Industry Forecast
AKYA's revenues are forecast to... subscribe to Premium to read more.
Forecast Revenue Growth vs Market Forecast

AKYA vs Medical Stocks

TickerPricePrice TargetUp/downsideConsensus
AKYA$1.32$1.51+14.39%Hold
MLSS$0.89N/AN/A
MBOT$2.50$9.00+260.00%Buy
NEPH$3.80N/AN/A
POCI$4.85N/AN/A
View Top Medical Stocks

Akoya Biosciences Stock Forecast FAQ

Is Akoya Biosciences Stock a good buy in 2025, according to Wall Street analysts?

The consensus among 3 Wall Street analysts covering (NASDAQ: AKYA) stock is to Hold AKYA stock.

Out of 3 analysts, 0 (0%) are recommending AKYA as a Strong Buy, 0 (0%) are recommending AKYA as a Buy, 3 (100%) are recommending AKYA as a Hold, 0 (0%) are recommending AKYA as a Sell, and 0 (0%) are recommending AKYA as a Strong Sell.

If you're new to stock investing, here's how to buy Akoya Biosciences stock.

What is AKYA's earnings growth forecast for 2025-2027?

(NASDAQ: AKYA) Akoya Biosciences's forecast annual earnings growth rate of N/A is not forecast to beat the US Medical Instruments & Supplies industry's average forecast earnings growth rate of 17.79%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 19.72%.

Akoya Biosciences's earnings in 2025 is -$47,533,000.On average, 4 Wall Street analysts forecast AKYA's earnings for 2025 to be -$41,521,270, with the lowest AKYA earnings forecast at -$45,885,367, and the highest AKYA earnings forecast at -$37,406,549. On average, 4 Wall Street analysts forecast AKYA's earnings for 2026 to be -$32,169,632, with the lowest AKYA earnings forecast at -$33,915,271, and the highest AKYA earnings forecast at -$30,423,993.

In 2027, AKYA is forecast to generate -$22,608,518 in earnings, with the lowest earnings forecast at -$24,937,700 and the highest earnings forecast at -$19,451,406.

What is AKYA's revenue growth forecast for 2025-2027?

(NASDAQ: AKYA) Akoya Biosciences's forecast annual revenue growth rate of 9.18% is forecast to beat the US Medical Instruments & Supplies industry's average forecast revenue growth rate of 8.53%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 9.8%.

Akoya Biosciences's revenue in 2025 is $79,961,000.On average, 2 Wall Street analysts forecast AKYA's revenue for 2025 to be $4,237,364,024, with the lowest AKYA revenue forecast at $4,020,904,792, and the highest AKYA revenue forecast at $4,453,873,131. On average, 2 Wall Street analysts forecast AKYA's revenue for 2026 to be $4,783,599,393, with the lowest AKYA revenue forecast at $4,614,621,542, and the highest AKYA revenue forecast at $4,952,627,121.

In 2027, AKYA is forecast to generate $5,240,707,425 in revenue, with the lowest revenue forecast at $5,144,797,033 and the highest revenue forecast at $5,336,667,693.

What is AKYA's forecast return on assets (ROA) for 2025-2027?

(NASDAQ: AKYA) forecast ROA is -20.07%, which is lower than the forecast US Medical Instruments & Supplies industry average of 12.62%.

What is AKYA's Price Target?

According to 3 Wall Street analysts that have issued a 1 year AKYA price target, the average AKYA price target is $1.51, with the highest AKYA stock price forecast at $1.80 and the lowest AKYA stock price forecast at $1.08.

On average, Wall Street analysts predict that Akoya Biosciences's share price could reach $1.51 by May 19, 2026. The average Akoya Biosciences stock price prediction forecasts a potential upside of 14.39% from the current AKYA share price of $1.32.

What is AKYA's Earnings Per Share (EPS) forecast for 2025-2027?

(NASDAQ: AKYA) Akoya Biosciences's current Earnings Per Share (EPS) is -$0.96. On average, analysts forecast that AKYA's EPS will be -$0.83 for 2025, with the lowest EPS forecast at -$0.92, and the highest EPS forecast at -$0.75. On average, analysts forecast that AKYA's EPS will be -$0.65 for 2026, with the lowest EPS forecast at -$0.68, and the highest EPS forecast at -$0.61. In 2027, AKYA's EPS is forecast to hit -$0.45 (min: -$0.50, max: -$0.39).

What is AKYA's forecast return on equity (ROE) for 2025-2027?

(NASDAQ: AKYA) forecast ROE is N/A, which is considered weak.
©2025 WallStreetZen
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletter
Stock Tools
Top Performing AnalystsStock ScreenerStock ForecastTrending StocksStrong Buy StocksHighest Earnings StocksBest Dividend Paying StocksStatisticsStock Market SectorsStock Market IndustriesHow to Buy Stocks Online
Stock Ideas
Buy The DipBiggest Stock Gainers TodayBiggest Stock Losers Today52 Week High Stocks52 Week Low StocksMost Active Stocks TodayMost Undervalued StocksBest Penny Stocks to Buy NowBest Stocks Under $5Best Stocks Under $10
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.